Samsung Biologics to acquire PolyPeptide Group for CHF 1.46B

Samsung Biologics has announced its intention to acquire PolyPeptide Group AG for CHF 1.46 billion in an all-cash deal. This strategic move aims to expand Samsung Biologics' capabilities beyond antibody and antibody-drug conjugate (ADC) therapies into peptide therapeutics. The acquisition will bolster its contract development and manufacturing organization (CDMO) platform, positioning it as a multi-modal CDMO. AI

RANK_REASON Acquisition of a significant company in the CDMO space by a major player. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on 36氪 (36Kr) →

• 44.31 Swiss francs
• antibody-drug conjugate
• CHF 1.46 billion
• contract manufacturing organization
• PolyPeptide Group AG
• Samsung Biologics

• product
• funding

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →